NDAORALCAPSULE
Approved
Feb 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CLEOCIN HYDROCHLORIDE (clindamycin hydrochloride) by Pfizer is mechanism of action clindamycin inhibits bacterial protein synthesis by binding to the 23s rna of the 50s subunit of the ribosome. First approved in 1970.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEOCIN HYDROCHLORIDE is a clindamycin-based oral antibiotic approved in 1970 that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, making it bacteriostatic. It is indicated for treatment of bacterial infections across multiple body systems. The product is a small-molecule oral capsule formulation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and transition planning for brand-team professionals.
Mechanism of Action
Mechanism of Action Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne
Started Mar 2015
245 enrolled
Acne
Career Relevance
Working on CLEOCIN HYDROCHLORIDE offers stable career opportunities in a mature, well-established product but limited growth potential due to approaching loss of exclusivity. Professionals should expect roles focused on defensive positioning, generic preparation, and operational excellence rather than expansion and innovation.
Brand Manager
Worked on CLEOCIN HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.